Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Berlex To Submit Angeliq NDA Response In March, Add Cardioprotective Data

Executive Summary

Schering AG's Berlex subsidiary expects to complete its response to FDA on its NDA for the hormone replacement therapy Angeliq in March

You may also be interested in...



Schering AG Makes Oncology A Primary Focus; Dermatology No Longer “Core”

Schering AG is establishing a new global oncology business unit that will be headquartered in the U.S

Schering AG Makes Oncology A Primary Focus; Dermatology No Longer “Core”

Schering AG is establishing a new global oncology business unit that will be headquartered in the U.S

Seasonale DTC Ads Will Help “Mainstream” Extended-Regimen OCs, Barr Says

Barr is hoping to "mainstream" the concept of extended-regimen oral contraceptives with a direct-to-consumer campaign for Seasonale

Related Content

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel